J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers and D. M. Parkinm “GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10,” International Agency for Research on Cancer, Lyon, 2010. http://globocan.iarc.fr
 J. Coronel, L. Cetina, M. Candelaria, A. González-Fierro, D. Arias, D. Cantu, et al., “Weekly Topotecan as Secondor Third-Line Treatment in Patients with Recurrent or Metastatic Cervical Cancer,” Medical Oncology, Vol. 26, No. 2, 2009, pp. 210-214. doi:10.1007/s12032-008-9108-5
 L. A. G. Ries, M. P. Eisner, C. L. Kosary, B. F. Hankey, B. A. Miller, L. Clegg, et al., “SEER Cancer Statistics Review, 1973-1998,” National Cancer Institute, Bethesda, 2012. http://seer.cancer.gov/ Publications/CSR1973_1998/2001
 J. V. Fiorica, J. A. Blessing, L. V. Puneky, A. A. Secord, J. S. Hoffman, S. D. Yamada, et al., “A Phase II Evaluation of Weekly Topotecan as a Single Agent Second Line Therapy in Persistent or Recurrent Carcinoma of the Cervix: A Gynecologic Oncology Group Study,” Gynecologic Oncology, Vol. 115, No. 2, 2009, pp. 285-289. doi:10.1016/j.ygyno.2009.07.024
 P. Boabang, C. M. Kurbacher, H. Kohlhagen, A. Waida and B. K. Amo-Takyi, “Anti-Neoplastic Activity of Topotecan versus Cisplatin, Etoposide and Paclitaxel in Four Squamous Cell Cancer Cell Lines of the Female Genital Tract Using an ATP-Tumor Chemosensitivity Assay,” Anticancer Drugs, Vol. 11, No. 10, 2000, pp. 843-848.
 K. Noda, H. Sasaki, K. Yamamoto, T. Yamamoto, R. Nishimura, T. Sugiyama, et al., “Phase II Trial of Topotecan for Cervical Cancer of the Uterus,” Proceedings of the American Society of Clinical Oncologists, Vol. 15, 1996, p. 754.
 M. A. Bookman, J. A. Blessing, P. Hanjani, T. J. Herzog and W. A. Andersen, “Topotecan in Squamous Cell Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group,” Gynecologic Oncology, Vol. 77, No. 3, 2000, pp. 446-449. doi:10.1006/gyno.2000.5807
 N. R. Abu-Rustum, S. Lee and L. S. Massad, “Topotecan for Recurrent Cervical Cancer after Platinum-Based Therapy,” International Journal of Gynecological Cancer, Vol. 10, No. 4, 2000, pp. 285-288. doi:10.1046/j.1525-1438.2000.010004285.x
 D. H. Moore, J. A. Blessing, R. P. McQuellon, H. T. Thaler, D. Cella, J. Benda, et al., “Phase III Study of Cisplatin with or without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study,” Journal of Clinical Oncology, Vol. 22, No. 15, 2004, pp. 3113-3119.
 F. Zagouri, T. N. Sergentanis, D. Chrysikos, M. Filipits and R. Bartsch, “Molecularly Targeted Therapies in Cervical Cancer. A Systematic Review,” Gynecologic Oncology, Vol. 126, No. 2, 2012, pp. 291-303. doi:10.1016/j.ygyno.2012.04.007
 B. J. Monk, M. W. Sill, R. A. Burger, H. J. Gray, T. E. Buekers and L. D. Roman, “Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study,” Journal of Clinical Oncology, Vol. 27, No. 7, 2009, pp. 1069-1074. doi:10.1200/JCO.2008.18.9043
 A. Nogueira-Rodrigues, C. C. Carmo, C. Viegas, F. Erlich, C. Camis?o, K. Font?o, et al., “Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer,” Clinical Cancer Research, Vol. 14, No. 19, 2008, pp. 6324-6329. doi:10.1158/1078-0432.CCR-07-5112